186 related articles for article (PubMed ID: 35073787)
1. Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications.
Pinky PD; Pfitzer JC; Senfeld J; Hong H; Bhattacharya S; Suppiramaniam V; Qureshi I; Reed MN
Neuroscientist; 2023 Aug; 29(4):461-471. PubMed ID: 35073787
[TBL] [Abstract][Full Text] [Related]
2. Impairments of glutamatergic synaptic transmission in Alzheimer's disease.
Zott B; Konnerth A
Semin Cell Dev Biol; 2023 Apr; 139():24-34. PubMed ID: 35337739
[TBL] [Abstract][Full Text] [Related]
3. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
[TBL] [Abstract][Full Text] [Related]
4. Dysfunction of NMDA receptors in Alzheimer's disease.
Zhang Y; Li P; Feng J; Wu M
Neurol Sci; 2016 Jul; 37(7):1039-47. PubMed ID: 26971324
[TBL] [Abstract][Full Text] [Related]
5. Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice" on page 513.
Gulyaeva NV
J Neurochem; 2021 Feb; 156(4):399-402. PubMed ID: 33276416
[TBL] [Abstract][Full Text] [Related]
6. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.
Mota SI; Ferreira IL; Rego AC
Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316
[TBL] [Abstract][Full Text] [Related]
7. Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.
Sokolow S; Luu SH; Nandy K; Miller CA; Vinters HV; Poon WW; Gylys KH
Neurobiol Dis; 2012 Jan; 45(1):381-7. PubMed ID: 21914482
[TBL] [Abstract][Full Text] [Related]
8. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic Glutamate Receptors in Alzheimer's Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future.
Srivastava A; Das B; Yao AY; Yan R
J Alzheimers Dis; 2020; 78(4):1345-1361. PubMed ID: 33325389
[TBL] [Abstract][Full Text] [Related]
10. The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy.
Bukke VN; Archana M; Villani R; Romano AD; Wawrzyniak A; Balawender K; Orkisz S; Beggiato S; Serviddio G; Cassano T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050345
[TBL] [Abstract][Full Text] [Related]
11. Post-synaptic scaffolding protein interactions with glutamate receptors in synaptic dysfunction and Alzheimer's disease.
Proctor DT; Coulson EJ; Dodd PR
Prog Neurobiol; 2011 Apr; 93(4):509-21. PubMed ID: 21382433
[TBL] [Abstract][Full Text] [Related]
12. RAPGEF2 mediates oligomeric Aβ-induced synaptic loss and cognitive dysfunction in the 3xTg-AD mouse model of Alzheimer's disease.
Jang YN; Jang H; Kim GH; Noh JE; Chang KA; Lee KJ
Neuropathol Appl Neurobiol; 2021 Aug; 47(5):625-639. PubMed ID: 33345400
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking.
Guntupalli S; Widagdo J; Anggono V
Neural Plast; 2016; 2016():3204519. PubMed ID: 27073700
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.
Paula-Lima AC; Brito-Moreira J; Ferreira ST
J Neurochem; 2013 Jul; 126(2):191-202. PubMed ID: 23668663
[TBL] [Abstract][Full Text] [Related]
17. The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease.
Rudy CC; Hunsberger HC; Weitzner DS; Reed MN
Aging Dis; 2015 Mar; 6(2):131-48. PubMed ID: 25821641
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease.
Rodriguez-Perdigon M; Tordera RM; Gil-Bea FJ; Gerenu G; Ramirez MJ; Solas M
Hippocampus; 2016 Oct; 26(10):1303-12. PubMed ID: 27258819
[TBL] [Abstract][Full Text] [Related]
19. Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.
Zeng Y; Zhang J; Zhu Y; Zhang J; Shen H; Lu J; Pan X; Lin N; Dai X; Zhou M; Chen X
J Neurochem; 2015 Apr; 133(1):38-52. PubMed ID: 25661995
[TBL] [Abstract][Full Text] [Related]
20. The synapse as a treatment avenue for Alzheimer's Disease.
Peng L; Bestard-Lorigados I; Song W
Mol Psychiatry; 2022 Jul; 27(7):2940-2949. PubMed ID: 35444256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
